Pulmonary Hypertension Clinical Trials
Early phase studies examining new targets with novel clinical end-points. Current and recent examples include:
- Chief Investigator of randomised trial of intravenous iron in idiopathic pulmonary arterial hypertension (IPAH)
- Chief Investigator (UK) for safety and efficacy study of pulmonary artery denervation with high-energy ultrasound
- Open-label dose ranging trial of dicholoracetate in IPAH
- Anti-IL-6 in IPAH and connective-tissue PAH
- Chief Investigator (UK) in Phase II study of Macitentan in chronic thromboembolic PH
- Intravenous apelin on resting and exercise haemodynamics in PAH
Late phase with novel end-points:
- Chief Investigator (UK) for activity-based exploratory outcome measures in randomised trial of IP3 agonist in PAH
Pulmonary Embolism
- Physiological impact of chronic thromboembolic disease
- Genetic and molecular profiling of pulmonary embolism
Cardiopulmonary Physiology
- Physiological phenotyping of pulmonary vascular diseases with exercise, haemodynamics and wave-intensity analysis
- Using exercise endpoints in clinical trials